Allen Bond

Blood Cancer Drugs Market : Latest Innovations, Drivers, Dynamics And Strategic Analysis, Challenges by 2023

Press Release   •   Apr 13, 2018 13:16 IST

A latest report has been added to the wide database of Blood Cancer Drugs Market by Infinium Global Research. This report studies the Blood Cancer Drugs Market by product (rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza, kyprolis, adcetris, and others) market status and outlook of global and major regions, from manufacturers, and end industries. The objective of the study is to identify market sizes of different segments & countries in recent years and to forecast the values for the next six years. Blood Cancer Drugs Market provides opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the major companies in the Blood Cancer Drugs Market. According to the report the Global Blood Cancer Drugs Market is projected to grow at a CAGR between 10.5% to 11.5% in terms of value over the period of 2017-2023.

Get Sample Copy of this Report: - https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/20

The higher costs of blood cancer drugs and therapies and the lack of supportive reimbursement policies and insurance coverage for blood cancer therapies in many regions are the major restraints for the global blood cancer drugs market. Biosimilars of biological drugs and generics of chemical drugs for cancer is expected to provide opportunity for pharmaceutical companies to expand in the developing and least developed countries, where the high costs of traditional blood cancer drugs are unaffordable for patients, during the forecast period. Providing cost effective blood cancer drugs to the patients will be a major challenge for the major pharmaceutical companies, due to the high investments required for research and development and manufacturing, during the forecast period.

Segments Covered:

The report segments the global blood cancer drugs market by product and region. On the basis of product, the market is segmented as rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza, kyprolis, adcetris, and others.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. North American region is the largest blood cancer drugs market, due to the presence of advanced diagnostic facilities and numerous blood cancer patients in USA. Presence of good healthcare facilities for cancer related treatments and affordability among public owing to the favorable reimbursement and insurance policies drive the growth of the North American blood cancer drugs market. Moreover, the presence of major Pharmaceutical companies in the region and their huge investments in research and development of blood cancer drugs is yielding new effective blood cancer drugs in the region. The increasing awareness and preference for immunotherapy due to efficiency is expected to drive the North American blood cancer market during the forecast period. Presence of large geriatric population and good healthcare facilities for cancer treatments drive the European blood cancer drugs market. Due high rate of diagnosis of blood cancer at initial stages and awareness about treatments among patients, the demand for the blood cancer drugs is high in Europe and it drives the growth of the market. The expiry of patents of major blood cancer drugs is expected to drive the growth of manufacturing of generic blood cancer drugs in near future.

Moreover, Europe has the policy to promote biologics and biosimilar drugs as an alternative for chemotherapeutic drugs and it is expected to drive the European blood cancer drugs market. The initiatives of major pharmaceutical companies to expand the operations in Presence of huge population, increasing awareness about the blood cancer, investments by governments to improved healthcare facilities for cancer treatments and promotion of alternative therapies such as immunotherapy and biologics are expected to drive the growth of the Asia-Pacific blood cancer market. Low cost generic and biosimilar drugs for blood cancer are expected to generate more demand in the Asia-Pacific blood cancer drugs market during the forecast period.

Companies Profiled:

Amgen Inc,

AstraZeneca PLC,

AstellasPharmaInc,

Bayer AG,

Bristol-Myers Squibb Company,

Celgene Corporation,

Eli Lilly,

F.Hoffmann-La Roche Ltd.,

Johnson & Johnson,

Novartis,

Pfizer Inc,

Takeda Pharmaceutical Company Ltd,

AbbVie Inc.

Make an Enquiry: - https://www.infiniumglobalresearch.com/Reports/MakeEnquiryRequest/20

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of blood cancer drugs globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and DRO analysis of blood cancer drugs. Moreover, the study highlights current market trends and provides forecast from 2016 to 2023. We also have highlighted future trends in the blood cancer drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the blood cancer drugs market to understand the present and future trends in this market and formulate their strategies accordingly

Table of Contents:-

1. Preface

1.1 Report Description

1.2 Research Methods

1.3 Research Approaches

2. Executive Summary

3. Global Blood Cancer Drugs Market Overview

3.1 Introduction

3.2 Market Dynamics

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunities

3.3 Porter’s Five Forces Analysis

3.4 IGR – Growth Matrix Analysis

3.5 Competitive Landscape in the Blood Cancer Drugs Market

4. Global Blood Cancer Drugs Market Analysis, by Product 2017 – 2023

4.1 Rituaxan/Mabthera (Rituximab)

4.2 Gleevac/Glivec (Imatinib)

4.3 Revlimid (Lenalidomide)

4.4 Velcade (Bortezomib)

4.5 Tasigna (Nilotinib)

4.6 Pomalyst (Pomalidomide)

4.7 Vidaza (Azacitidine)

4.8 Kyprolis (Carfilzomib)

4.9 Adcetris (Brentuximab Vedotin)

4.10 Others

5. Global Blood Cancer Drugs Market Analysis, by Region 2017 – 2023

5.1 North America

5.1.1 North America Blood Cancer Drugs Market by Product

5.1.2 North America Blood Cancer Drugs Market by Country

5.2 Europe

5.2.1 Europe Blood Cancer Drugs Market by Product

5.2.2 Europe Blood Cancer Drugs Market by Country

5.3 Asia-Pacific

5.3.1 Asia-Pacific Blood Cancer Drugs Market by Product

5.3.2 Asia-Pacific Blood Cancer Drugs Market by Product

5.4 Rest of the World (RoW)

5.4.1 RoW Blood Cancer Drugs Market by Product

5.4.2 RoW Blood Cancer Drugs Market by Sub-region

6. Company Profiles

6.1 Amgen Inc

6.2 AstraZeneca PLC

6.3 Astellas Pharma Inc

6.4 Bayer AG

6.5 Bristol-Myers Squibb Company

6.6 Celgene Corporation

6.7 Eli Lilly

6.8 F.Hoffmann-La Roche Ltd

6.9 Johnson & Johnson

6.10 Novartis

6.11 Pfizer Inc

6.12 Takeda Pharmaceutical Company Ltd

6.13 AbbVie Inc

Click the Below Full Report Link: - https://www.infiniumglobalresearch.com/healthcare_medical_devices/blood_cancer_drugs_market